She was seven months old when her parents first noticed it. Not the peaceful stillness of sleep, but something heavier. Her arms, which had once reached for hanging toys, had grown quiet. Her head, once held with the wobbly determination of a healthy infant, began to drift. The milestones that seemed to be arriving suddenly began moving in reverse.
Weeks later, a child neurologist delivered the diagnosis: spinal muscular atrophy type 1, or SMA. For most of medical history, that diagnosis carried a devastating certainty. SMA destroys the motor neurons responsible for movement, swallowing, and breathing. Infants with the most severe form rarely survived beyond early childhood. Physicians could explain what was happening. They could provide supportive care. But they could not stop the disease itself.
Today, they often can. In one of the most remarkable scientific achievements of the modern era, treatments such as onasemnogene abeparvovec, nusinersen, and risdiplam have altered the natural history of SMA. One treatment delivers a functional copy of the missing gene through a single infusion. Others increase production of the deficient protein through targeted molecular mechanisms. Children who once would have steadily lost motor function are now sitting, standing, speaking, and walking.
The transformation has been so dramatic that it has changed what physicians expect to see. What was once an invariably fatal neurodegenerative disease has become a condition in which timing may determine outcome. And that is precisely where a new problem begins.
Real physician voices, twice a week
Free, and one click to unsubscribe.
For decades, families affected by rare neurological disease endured what became known as the “diagnostic odyssey“: years of referrals, inconclusive tests, specialist visits, and uncertainty before finally learning what was wrong.
Advances in genomic medicine have fundamentally changed the landscape of pediatric neurology. Rapid genome sequencing can identify disease-causing variants in critically ill children within days. Expanded newborn screening programs are detecting disorders before symptoms emerge. Gene therapies, antisense oligonucleotides, enzyme replacement therapies, and other targeted interventions are creating treatment opportunities that would have seemed impossible a generation ago.
The diagnostic odyssey is becoming shorter. A new odyssey has emerged in its place. It begins after the diagnosis.
As a medical student pursuing child neurology, I have become increasingly interested in how advances in neurogenetics are reshaping care for children with rare disease. During my clinical experiences and mentorship from leaders in the field, I have been struck by how often conversations center not on discovering a diagnosis, but on obtaining the treatment that follows.
Today, many families find themselves navigating a maze of prior authorizations, coverage reviews, appeals, specialty referrals, treatment-center requirements, and administrative delays. The tragedy is no longer simply that a child cannot obtain a diagnosis. Increasingly, the tragedy is that we know exactly what disease a child has, understand the molecular mechanism causing it, possess a therapy capable of changing its course, and still struggle to deliver treatment in time.
In pediatric neurology, time is not merely a scheduling issue. It is biology. A motor neuron lost to SMA cannot be recovered. Neurodegenerative diseases do not pause while paperwork moves through administrative channels. Therapeutic windows are often measured in months, sometimes weeks. Studies of presymptomatic SMA treatment have shown that infants treated before symptom onset achieve meaningfully better motor outcomes than those treated after, a finding that makes every administrative delay a clinical event, not merely an inconvenience. Every delay carries consequences that no subsequent approval can reverse.
For families confronting SMA, every week between diagnosis and treatment represents motor neurons that may never be recovered. The difference between immediate treatment and delayed treatment may shape an entire lifetime of function.
The irony is difficult to ignore. Medicine has learned how to rewrite DNA. Yet we still struggle to navigate the systems required to deliver those therapies. The challenge extends beyond insurance alone. The deeper problem is that medicine has built an extraordinary discovery infrastructure without building an equally robust delivery infrastructure.
Over the past two decades, health care systems invested heavily in gene discovery, sequencing technologies, newborn screening programs, precision diagnostics, and therapeutic development. Those investments have transformed the possibilities available to children with rare neurological disease. Far less attention has been paid to what happens next.
Who coordinates care after a diagnosis is made? Who ensures rapid access to specialized testing? Who guides families through a rapidly evolving therapeutic landscape? Who builds systems capable of moving patients efficiently from screening to diagnosis, diagnosis to treatment, and treatment to long-term follow-up?
Scientific innovation transformed conditions that once carried only supportive options into diseases with targeted therapies. Yet health care systems have not always evolved at the same pace. Precision medicine now needs a counterpart: precision delivery.
That means building systems specifically designed for time-sensitive genetic disease. It means embedding genetic counselors and nurse navigators directly into pediatric neurology programs, not as add-ons, but as core members of the clinical team. Programs that have done this, including several academic neurogenetics centers that have built integrated SMA treatment pathways, have demonstrated that coordinated navigation can compress the time between diagnosis and treatment initiation. At several centers, newborn screening results trigger automatic referral pathways involving neurology, genetics, pharmacy, and care coordination teams, reducing delays that previously stretched for weeks. The model exists. It is not yet the standard.
It also means creating streamlined pathways for genetic testing and treatment authorization rather than requiring patients to navigate a patchwork of referrals and approvals. It means developing regional neurogenetics centers capable of integrating diagnosis, treatment, and long-term follow-up under one roof. And it means measuring success not simply by whether a diagnosis was made, but by how quickly a child receives treatment after that diagnosis. In an era when outcomes may depend on weeks rather than years, time-to-treatment may become as important a quality metric as diagnostic accuracy itself.
None of these solutions are as scientifically glamorous as gene therapy. None will appear on the cover of major medical journals as breakthrough discoveries. Yet they may determine whether the breakthroughs already sitting in our laboratories ever reach the children they were designed to help.
SMA illustrates this challenge with unusual clarity. For perhaps the first time in medical history, physicians may identify a newborn with a devastating neurogenetic disease, confirm the diagnosis genetically, and possess the ability to intervene before symptoms emerge. This is a triumph of science. It is also a test of whether health care systems can translate scientific possibility into clinical reality. And SMA will not be the last test.
Across pediatric neurology, similar questions are emerging in epileptic encephalopathies, neurometabolic disorders, leukodystrophies, and other genetic conditions for which earlier diagnosis increasingly creates opportunities for intervention. As more therapies arrive, the gap between discovering what is possible and delivering what is possible may become one of the defining challenges of the field.
For generations, the greatest challenge in rare pediatric neurology was discovering what was wrong. Today, diagnosis is increasingly becoming the starting line rather than the finish line.
Somewhere today, another infant will be identified through newborn screening with a disease that would have been untreatable a generation ago. The science will exist. The diagnosis may arrive within days. The therapy may already be available. The question is whether the system can move quickly enough to matter.
The defining tragedy of rare pediatric neurological disease used to be not knowing. Increasingly, the defining tragedy is knowing and still being unable to act in time. That is not a failure of genetics. It is a failure of our health care delivery system. And it is a failure that clinicians, health systems, and policymakers have the knowledge and the means to correct.
Discovery built the future. Now delivery must reach it.
Shaan R. Mody is a medical student.
